Sanofi and Al­ny­lam plunge in­to PhI­II with a ri­val to Roche’s top he­mo­phil­ia drug

In­ves­ti­ga­tors won’t pull back the cov­ers from the lat­est mid-stage da­ta on fi­tusir­an for a few days yet, but Al­ny­lam $AL­NY and its Big Phar­ma part­ners at Sanofi Gen­zyme $SNY have fired the starter pis­tol on an am­bi­tious Phase III pro­gram for the an­tithrom­bin he­mo­phil­ia drug that will look to field a ri­val to Roche’s close­ly watched emi­cizum­ab (ACE910).

The com­pa­nies out­lined their plans for the three stud­ies in the piv­otal ef­fort, which will col­lec­tive­ly re­quire 250 pa­tients with top-line da­ta due in mid- to late-2019.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.